Malaysia
Search
Sign In
Change Password
Points
Sign Out
Top Medical News
Diets enriched with either pistachios or walnuts appear to be better alternatives than other nut-enriched diets for lowering triglycerides, low-density lipoprotein (LDL) cholesterol and total cholesterol (TC), suggest the results of a meta-analysis.
Microcirculatory function appears to play a role in diabetic kidney disease (DKD) in type 2 diabetes patients, a new study has shown. Perfusion index may be a novel indicator of DKD.
Middle-aged women with polycystic ovary syndrome (PCOS) exhibit only a moderately unfavourable cardiometabolic profile despite having an increased body mass index (BMI) and waist circumference, as reported in a study.
Big abdominal circumference in men may predict recurrence of cardiovascular events after a first myocardial infarction (MI) and this could well be a good prognosticator following acute coronary syndrome (ACS), a retrospective analysis has shown.
Individuals with new-onset prediabetes/diabetes after non-necrotizing acute pancreatitis (NODAP) more often have reduced insulin sensitivity, β-cell compensation, and no significant change in postprandial levels of glucagon and pancreatic polypeptide, suggests a study.
Postprandial hyperglycaemia may increase the risk of incident diabetic retinopathy (DR) in patients with type 2 diabetes (T2D) independently of glycated haemoglobin (HbA1c) status, reports a new study.
Metabolic syndrome (MS) and its components contribute to an increased risk of developing hepatocellular carcinoma (HCC) in individuals with hepatitis B virus (HBV) infection, a study has found.
Special Reports
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab
At a recent Boehringer Ingelheim-sponsored symposium held in conjunction with the 10th Malaysian Endocrine and Metabolic Society Annual Congress, two distinguished speakers spoke on the latest updates in glucose-lowering therapy for the treatment for type 2 diabetes mellitus (T2DM) and highlighted some important cardiovascular outcome trial results of these antidiabetic agents.
At the recent 10th Malaysian Endocrine and Metabolic Society (MEMS) Annual Congress(MAC) held in Hilton Kuala Lumpur, Dr Wong Ming, a consultant endocrinologist from Sunway Medical Centre, spoke on the role of non–high-density lipoprotein cholesterol (non–HDL-c) as an emerging marker and treatment target for cardiovascular (CV) disease. Additionally, she also highlighted the role of fenofibrate in delaying and preventing diabetic retinopathy (DR).
At a recent Abbott lunch symposium held in conjunction with the joint 12th International Diabetes FederationWestern Pacific Region Congress & 10th Asian Association for the Study of Diabetes Scientific Meeting in KualaLumpur, Professor Shashank R. Joshi extensively discussed the issue of diabetes in obesity and the role of nutritionalintervention in addressing this growing problem.
At the recent 12th IDF-WPR Congress and 10th AASD Scientific Meeting held at Kuala Lumpur Convention Centre, the importance of glycaemic control and the practical management of type 2 diabetes mellitus (T2DM) were highlighted by two international speakers, Dr Sanjay Kalra from India and Professor Jean Claude Mbanya from Cameroon.
Dapagliflozin 5 mg and 10 mg FC tab
At the Abbott-sponsored symposium held during the 9th Malaysian Endocrine and Metabolic Society Annual Congres sat Hilton Kuala Lumpur, Dr Zanariah Hussein shared her insights into the important role of an emerging marker of hypercholesterolaemia, and its relationship with cardiovascular (CV) and diabetic retinopathy (DR) risks.
Conference Reports
Multiple analyses of the DAPA-HF* trial have shown that dapagliflozin, in addition to standard therapy, reduces the risk of multiple heart failure (HF) outcomes including cardiovascular (CV) death and hospitalization for HF (HHF) in patients with HF and reduced ejection fraction (HFrEF), with the effects consistent regardless of age and type 2 diabetes (T2D) status.
Slideshow: Highlights from the American Heart Association (AHA) Scientific Sessions 2019
Podcast: Professor Carolyn Lam states that dapagliflozin appears to meet the three major aims of HFrEF treatment, ie, reduced mortality, reduced hospitalization, and improved quality of life.
Podcast: Professor John McMurray says that the DAPA-HF trial demonstrates the efficacy of dapagliflozin in reducing the risk of heart failure in patients with HFrEF with and without T2D.
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Upfront combination therapy with metformin and the DPP-4* inhibitor vildagliptin may improve glycaemic durability in patients newly diagnosed with type 2 diabetes (T2D) compared with sequential therapy with metformin monotherapy followed by vildagliptin, results from the VERIFY** trial showed.
The novel dual GIP* and GLP-1** receptor agonist tirzepatide demonstrated clinically meaningful improvements in glycaemic control and weight loss in patients with type 2 diabetes (T2D), according to data presented at EASD 2019.
Multimedia
